Display options
Cite
Giancola ML, Lorenzini P, Cingolani A, et al. Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders. AIDS Res Treat. 2012;2012:708456doi: 10.1155/2012/708456.
Giancola, M. L., Lorenzini, P., Cingolani, A., Baldini, F., Bossolasco, S., Bini, T., Monno, L., Picchi, G., d'Arminio Monforte, A., Cinque, P., Tozzi, V., & Antinori, A. (2012). Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders. AIDS research and treatment, 2012708456. https://doi.org/10.1155/2012/708456
Giancola, Maria Letizia, et al. "Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders." AIDS research and treatment vol. 2012 (2012): 708456. doi: https://doi.org/10.1155/2012/708456
Giancola ML, Lorenzini P, Cingolani A, Baldini F, Bossolasco S, Bini T, Monno L, Picchi G, d'Arminio Monforte A, Cinque P, Tozzi V, Antinori A. Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders. AIDS Res Treat. 2012;2012:708456. doi: 10.1155/2012/708456. Epub 2012 Aug 26. PMID: 22957220; PMCID: PMC3432519.
Copy Download .nbib Format: NLM
Share it on

AIDS Res Treat. 2012;2012:708456. doi: 10.1155/2012/708456. Epub 2012 Aug 26.

Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders.

AIDS research and treatment

Maria Letizia Giancola, Patrizia Lorenzini, Antonella Cingolani, Francesco Baldini, Simona Bossolasco, Teresa Bini, Laura Monno, Giovanna Picchi, Antonella d'Arminio Monforte, Paola Cinque, Valerio Tozzi, Andrea Antinori

Affiliations

  1. Clinical Department, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Via Portuense, 292, 00149 Rome, Italy.

PMID: 22957220 PMCID: PMC3432519 DOI: 10.1155/2012/708456

Abstract

The aim of the present study was to analyse the effect of antiretroviral (ARV) therapy and single antiretroviral drugs on cerebrospinal fluid (CSF) HIV-RNA burden in HIV-infected patients affected by neurological disorders enrolled in a multicentric Italian cohort. ARVs were considered "neuroactive" from literature reports. Three hundred sixty-three HIV-positive patients with available data from paired plasma and CSF samples, were selected. One hundred twenty patients (33.1%) were taking ARVs at diagnosis of neurological disorder. Mean CSF HIV-RNA was significantly higher in naïve than in experienced patients, and in patients not taking ARV than in those on ARV. A linear correlation between CSF HIV-RNA levels and number of neuroactive drugs included in the regimen was also found (r = -0.44, P < 0.001). Low -plasma HIV-RNA and the lack of neurocognitive impairment resulted in independently associated to undetectable HIV-RNA. Taking nevirapine or efavirenz, or regimen including NNRTI, NNRTI plus PI or boosted PI, was independently associated to an increased probability to have undetectable HIV-RNA in CSF. The inclusion of two or three neuroactive drugs in the ARV regimen was independently associated to undetectable viral load in CSF. Our data could be helpful in identifying ARV regimens able to better control HIV replication in the CNS sanctuary, and could be a historical reference for further analyses.

References

  1. AIDS. 2002 Sep 27;16(14):1867-76 - PubMed
  2. J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):174-82 - PubMed
  3. Ann Neurol. 1997 Nov;42(5):679-88 - PubMed
  4. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):168-73 - PubMed
  5. AIDS. 2003 May 23;17(8):1167-72 - PubMed
  6. Ann Neurol. 1997 Nov;42(5):689-98 - PubMed
  7. AIDS. 2000 Dec 22;14(18):2869-76 - PubMed
  8. AIDS. 1998 Oct 22;12(15):1941-55 - PubMed
  9. Arch Neurol. 2008 Jan;65(1):65-70 - PubMed
  10. J Acquir Immune Defic Syndr. 2006 Mar;41(3):332-7 - PubMed
  11. AIDS. 2009 Jul 17;23(11):1359-66 - PubMed
  12. Ann Neurol. 1993 Apr;33(4):343-9 - PubMed
  13. Antimicrob Agents Chemother. 2005 Jun;49(6):2504-6 - PubMed
  14. AIDS. 2000 Jun 16;14(9):1187-94 - PubMed
  15. AIDS. 2009 May 15;23(8):907-15 - PubMed
  16. Clin Infect Dis. 2005 Dec 15;41(12):1787-93 - PubMed
  17. Antivir Ther. 2006;11(7):833-7 - PubMed
  18. J Antimicrob Chemother. 2011 Feb;66(2):354-7 - PubMed
  19. AIDS. 2010 Jun 1;24(9):1243-50 - PubMed
  20. Ann Neurol. 2008 Feb;63(2):213-21 - PubMed
  21. Ann Neurol. 2004 Mar;55(3):320-8 - PubMed
  22. JAMA. 1998 Jul 1;280(1):67-71 - PubMed
  23. Neurology. 2002 Aug 13;59(3):342-7 - PubMed
  24. AIDS. 2007 Sep 12;21(14):1915-21 - PubMed
  25. Neurology. 2001 Aug 14;57(3):542-4 - PubMed
  26. J Neuroimmunol. 2004 Dec;157(1-2):3-10 - PubMed
  27. J Infect Dis. 2001 May 1;183(9):1318-27 - PubMed
  28. J Infect Dis. 2010 Dec 15;202(12):1819-25 - PubMed
  29. J Antimicrob Chemother. 2012 Feb;67(2):299-311 - PubMed
  30. AIDS. 2010 Jan 2;24(1):123-37 - PubMed
  31. Neurology. 2003 Apr 22;60(8):1388-90 - PubMed
  32. Arch Neurol. 2002 Jun;59(6):923-8 - PubMed
  33. AIDS. 2005 Jun 10;19(9):949-52 - PubMed
  34. Ann Neurol. 2004 Sep;56(3):416-23 - PubMed
  35. Ann Neurol. 1997 Nov;42(5):675-8 - PubMed
  36. Lancet. 2007 Aug 4;370(9585):407-13 - PubMed
  37. Clin Infect Dis. 2010 Mar 1;50(5):773-8 - PubMed

Publication Types